STOCK ISSUANCE AGREEMENTStock Issuance Agreement • August 10th, 2015 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York
This Agreement (“Agreement”) is made and entered into as of August 10, 2015 (the “Effective Date”), by and among Synthetic Biologics, Inc., a Nevada corporation (the “Company”), and Intrexon Corporation, a Virginia corporation (“Intrexon”).
Exclusive Channel Collaboration AgreementExclusive Channel Collaboration Agreement • August 10th, 2015 • Synthetic Biologics, Inc. • Pharmaceutical preparations • New York
This Exclusive Channel Collaboration Agreement (the “Agreement”) is made and entered into effective as of August 10, 2015 (the “Effective Date”) by and between Intrexon Corporation, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and Synthetic Biologics, Inc., a Nevada corporation having its principal place of business at 617 Detroit Street, Suite 100, Ann Arbor, MI 48104 (“Synthetic”). Intrexon and Synthetic may be referred to herein individually as a “Party”, and collectively as the “Parties.”
SECOND AMENDMENT TO REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 10th, 2015 • Synthetic Biologics, Inc. • Pharmaceutical preparations
This Second Amendment to Registration Rights Agreement (the “Second Amendment”) is made and entered into as of August 10, 2015, by and among Synthetic Biologics, Inc., a Nevada corporation, previously known as Adeona Pharmaceuticals, Inc. (the “Company”), and Intrexon Corporation, a Virginia corporation (“Intrexon”) to amend the Registration Rights Agreement dated December 5, 2011, by and among the Company and Intrexon (the “Registration Rights Agreement”).
